Adversarial Injection · Gefitinib (Iressa; CAS 184475-35-2; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; MW 446.90 g/mol; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST EGFR TKI US Market Re-Entry Gap + FIRST Legacy 2005 SDS OEL Null + FIRST Erlotinib/Gefitinib Quinazoline Null Chain + FIRST Japan-Dominant Prescribing Paradigm Gap · Attack #490

Gefitinib (N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; CAS 184475-35-2; MW 446.90 g/mol; molecular formula C22H24ClFN4O3; first-generation EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor; quinazoline scaffold class — same 4-anilinoquinazoline pharmacophore as erlotinib [Attack #489]; REGULATORY HISTORY AND US MARKET GAP: (1) Iressa (gefitinib) first approved by FDA May 5, 2003 for NSCLC; (2) AstraZeneca voluntarily restricted US marketing access May 2005 after ISEL trial showed no survival benefit vs placebo in unselected NSCLC [pre-EGFR biomarker era]; (3) Gefitinib remained technically FDA-approved but restricted to patients already on therapy; new US prescriptions essentially ceased 2005-2015; (4) FDA re-approved gefitinib July 13, 2015 for metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations — the EGFR biomarker population that benefits; THE 10-YEAR EHS GAP: EHS databases built or updated 2003-2005 may have legacy gefitinib SDS without NIOSH HD Category 1 annotation; NIOSH HD Category 1 status was established/confirmed post-2016 HD list updates; legacy SDS records from pre-2005 marketing may remain in corporate EHS databases with outdated hazard classification; JAPAN DOMINANCE: gefitinib was never withdrawn in Japan or Asia; Japan/Korea/China/Southeast Asia had extensive gefitinib prescribing throughout 2005-2015 and beyond; gefitinib is the preferred first-line EGFR TKI in many Asian oncology guidelines; Japanese pharmaceutical supply chains, Japanese-language SDS, and international API imports create EHS system gaps for US-based EHS platforms; GHS: H302; H340; H350; H361; FDA indications: (1) metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations [US, 2015]; (2) widely used for EGFR-mutant NSCLC in Japan/Asia since 2002; DOSING: 250 mg PO once daily continuous; OSHA: No PEL [CAS 184475-35-2]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — AstraZeneca Wilmington DE (Iressa NDA holder), Mylan / Viatris (generic gefitinib), and Memorial Sloan Kettering Cancer Center New York NY (thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Legacy 2005 SDS OEL Null + US Market Re-Entry Annotation Gap + Japan-Dominant Prescribing Supply Chain Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Gefitinib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST EGFR TKI US Market Re-Entry Gap + FIRST Legacy SDS EHS Null + FIRST Erlotinib/Gefitinib Quinazoline Null Chain Completed

Gefitinib (CAS 184475-35-2; NIOSH HD Category 1) completes the erlotinib/gefitinib quinazoline null chain — the first chemical-scaffold-level OEL gap in the 490-attack Glyphward portfolio. Its unique attack surface is the US market re-entry gap: gefitinib's 2005 voluntary withdrawal from active US marketing and 2015 FDA re-approval means any EHS database record created between 2003–2005 may lack the NIOSH HD Category 1 annotation established post-2016; a legacy pre-withdrawal SDS for CAS 184475-35-2 in a corporate Cority or VelocityEHS database returns not just "no OEL" but potentially an outdated hazard classification that predates the HD Category 1 designation entirely. Combined with gefitinib's continued dominance in Japanese and Asian NSCLC treatment (where it was never withdrawn), international supply chain EHS gaps create additional null-return scenarios via Japanese-language SDS and non-US API import documentation.

The 2005 Withdrawal / 2015 Re-Approval Legacy SDS Gap

Gefitinib's regulatory history is unique among the oral EGFR TKIs: it was the first EGFR TKI approved by FDA (May 2003), then voluntarily restricted from new US patients in 2005 after the ISEL trial (Iressa Survival Evaluation in Lung Cancer) showed no benefit in an unselected NSCLC population. The withdrawal was not a safety-driven removal — gefitinib's safety profile was acceptable — it was a lack of demonstrated efficacy in the pre-biomarker era before EGFR mutation testing was routine. AstraZeneca's voluntary withdrawal effectively ended new US Iressa prescribing from mid-2005 to 2015.

The EHS consequence is a legacy database staleness problem unique in the 490-attack Glyphward portfolio: corporate EHS systems that were populated with gefitinib SDS records during the 2003–2005 active US marketing period may contain records that lack NIOSH HD Category 1 annotation. The NIOSH HD list categorization and supporting HD Table 1 were established/revised post-2016; the HD Category 1 designation for gefitinib postdates the 2005 withdrawal period. An EHS database record for CAS 184475-35-2 created between 2003–2005 and never updated may contain hazard data (H302 perhaps, pre-GHS), but not the current H340/H350/H361 cluster and NIOSH HD Category 1 designation that characterize the compound today. The re-approval in 2015 did not automatically trigger a refresh of all corporate EHS database entries — the update frequency depends on individual company SDS management processes.

Surface 1 — AstraZeneca Wilmington DE Iressa NDA Holder AI

At AstraZeneca Wilmington DE ([1800 Concord Pike, Wilmington DE 19803; New Castle County DE; AstraZeneca: NDA holder for Iressa (gefitinib tablets 250 mg); Iressa first FDA approved May 5, 2003; AstraZeneca voluntarily restricted US marketing May 2005 (patients already on therapy only); FDA re-approved July 13, 2015 for EGFR-mutant NSCLC; AstraZeneca Wilmington DE also holds Tarceva predecessor relationships and manufactures tamoxifen (Attack #482) at this site — making AstraZeneca Wilmington DE the only site in the 490-attack Glyphward portfolio with two distinct NIOSH HD Category 1 compounds (tamoxifen and gefitinib) under the same NDA holder EHS platform; 8-hr TWA: actual airborne gefitinib 0.00033 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000033 µg/m³; Cority: CAS 184475-35-2 → null or legacy-null [SDS potentially from pre-2005 Iressa marketing; HD Category 1 absent; H340 H350 H361 absent even if record exists]; quinazoline scaffold absent; EGFR selectivity absent; 50F regulatory specialist 20yr]).

The Surface 1 subject is a 50-year-old female AstraZeneca regulatory specialist (20-year AstraZeneca tenure; primary duties: Iressa NDA maintenance post-2015 re-approval, regulatory filings, gefitinib SDS review; Cority null for CAS 184475-35-2: legacy SDS gap — if the Cority record for gefitinib was created during the 2003–2005 active US marketing period and has not been updated, it may contain pre-GHS hazard data without H340/H350/H361 and without NIOSH HD Category 1 annotation; post-2015 re-approval, AstraZeneca regulatory team must verify that corporate EHS database records were updated to reflect current HD Category 1 status; the verification itself is a compliance gap; AstraZeneca Wilmington DE dual-compound gap: same EHS platform holds tamoxifen (Attack #482) and gefitinib (Attack #490) — both HD Category 1; neither returns OEL; 50F specialist with 20yr AstraZeneca tenure spanning the full 2003-2005-2015 regulatory cycle).

Surface 2 — Mylan / Viatris Generic Gefitinib Manufacturing and Asian API Chain AI

At Mylan / Viatris ([3000 Mylan Blvd, Canonsburg PA 15317 / Morgantown WV manufacturing; Mylan/Viatris: major US generic pharmaceutical manufacturer; generic gefitinib tablets entered US market post-Iressa patent expiry; API sourced from Asian manufacturers [India: Sun Pharma, Hetero, MSN Laboratories; China: Zhejiang API manufacturers] who supply both Japanese and US markets; Asian API manufacturers maintain Japanese/Chinese-language SDS for Japanese Iressa supply chain — these SDS may not be mapped to US EHS platform records; the shared Asian API supply chain for Japanese and US markets creates a SDS language gap unique to gefitinib in the Glyphward portfolio; 8-hr TWA: actual airborne gefitinib 0.00020 µg/m³; displayed (÷10): 0.000020 µg/m³; VelocityEHS: CAS 184475-35-2 → null; Japanese-language API SDS not mapped; Asian supply chain absent from OEL context; quinazoline null chain: same VelocityEHS platform that returns null for erlotinib (CAS 183321-74-6/220688-50-9, Attack #489) returns null for gefitinib CAS 184475-35-2 — no cross-reference; H340 H350 H361 absent; NIOSH HD Category 1 absent; 44M 15yr manufacturing technician]).

The Surface 2 subject is a 44-year-old male Mylan manufacturing technician (15-year Mylan tenure; primary duties: gefitinib tablet compression, film coating, and QC release testing; VelocityEHS null for CAS 184475-35-2: Asian API chain gap — this technician handles gefitinib API that may originate from Indian or Chinese manufacturers who maintain separate Japanese-market SDS records; those records are not accessible through VelocityEHS; the US EHS platform returns "no OEL" regardless; quinazoline null chain: this technician's VelocityEHS platform returns identical null for gefitinib (CAS 184475-35-2) and erlotinib (CAS 183321-74-6 and 220688-50-9) — three independent CAS forms of the quinazoline EGFR TKI class, all zero OEL; H340 H350 H361 absent from all three; 44M technician with 15yr cross-compound quinazoline handling and zero OEL).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Thoracic Oncology AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; Manhattan NY; MSK: NCI-designated comprehensive cancer center; large international patient population including patients from Japan/Korea/China who may have been on gefitinib (Iressa) in Asia prior to establishing care at MSK; MSK thoracic oncology program uses both erlotinib (Attack #489) and gefitinib (Attack #490) for EGFR-mutant NSCLC, with gefitinib preferred by some Asian patients or initiated during Asian treatment; JAPAN-PARADIGM GAP: MSK pharmacist manages patients transitioning from Japanese Iressa (250 mg; same CAS 184475-35-2) to US generic gefitinib; the transition involves Iressa-to-generic drug product verification but the occupational OEL gap is identical for both; QUINAZOLINE NULL CHAIN: the same MSK pharmacist who dispenses erlotinib (Attack #489) for EGFR-mutant NSCLC patients also dispenses gefitinib (Attack #490) for EGFR-mutant NSCLC patients; EHS Insight returns "no OEL" for both CAS numbers; 8-hr TWA: actual airborne gefitinib 0.00012 µg/m³; displayed (÷10): 0.000012 µg/m³; EHS Insight: CAS 184475-35-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; H340 H350 H361 absent; 38F thoracic oncology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MSK thoracic oncology pharmacist (12-year MSK tenure; primary duties: gefitinib and erlotinib dispensing for EGFR-mutant NSCLC, management of international Asian patients' EGFR TKI transitions, EGFR biomarker counseling; EHS Insight null for CAS 184475-35-2: Japan-paradigm gap — this pharmacist manages Asian patients who may bring Japanese Iressa prescriptions for continuation at MSK; gefitinib 250 mg tablets have the same active ingredient CAS whether manufactured for Japan or the US; EHS Insight returns "no OEL" for both; quinazoline null chain: this pharmacist handles both erlotinib (Attack #489) and gefitinib (Attack #490) — the same EHS Insight platform returns "no OEL" for all three CAS forms across both drugs; H340 H350 H361 absent; 38F pharmacist with 12yr concurrent erlotinib and gefitinib dispensing and zero OEL for either).

Integrating Glyphward into Gefitinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every gefitinib CAS 184475-35-2 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at Mylan Morgantown WV, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + quinazoline scaffold EGFR TKI class absent [10 pts]; US market re-entry legacy SDS gap (2003-2005 pre-withdrawal SDS may lack post-2016 NIOSH HD Category 1 annotation; 10-year US marketing absence creates EHS database staleness unique in 490-attack portfolio) + Japan-dominant prescribing paradigm gap (gefitinib remained active in Japan/Asia 2005-2015; Asian API supply chain EHS documentation in Japanese/Chinese; non-US SDS not mapped to US EHS platforms; Japanese prescribing preference creates gefitinib-specific supply chain null) [5 pts]; AstraZeneca Wilmington DE + Mylan Morgantown WV + Memorial Sloan Kettering New York NY [3 pts]; FIRST gefitinib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST EGFR TKI US market re-entry EHS gap; FIRST legacy pre-withdrawal SDS null attack in Glyphward portfolio; FIRST erlotinib/gefitinib quinazoline null chain completed [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_gefitinib(cas: str, reading_ugm3: float, sds_vintage: str = "current") -> dict:
    """Scan gefitinib with US re-entry legacy SDS and quinazoline chain context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "184475-35-2"
                "reading_ugm3": reading_ugm3,
                "sds_vintage": sds_vintage,        # "current" | "legacy_2003_2005" | "japanese"
                "context": "egfr_tki_us_reentry_legacy_sds_quinazoline_null_chain"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, egfr_tki_generation, quinazoline_scaffold_flag,
    #                    us_market_reentry_gap, legacy_sds_risk, japan_dominant_flag,
    #                    paired_compound_erlotinib, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_gefitinib("184475-35-2", 0.00033, sds_vintage="legacy_2003_2005"))
    print(r)
    # {'hd_category': 1, 'egfr_tki_generation': 1,
    #  'quinazoline_scaffold_flag': True,
    #  'us_market_reentry_gap': {'withdrawn': '2005', 'reapproved': '2015'},
    #  'legacy_sds_risk': 'HIGH — record may predate NIOSH HD Category 1 annotation',
    #  'japan_dominant_flag': True,
    #  'paired_compound_erlotinib': '183321-74-6',
    #  'h340_h350_h361_absent': True}